Acadia Pharmaceuticals | ACAD - Ebitda



金融业
股票价格
USD
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 4.9B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


Ebitda 更改 日
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
ALKERMES USD 139.22M 58.96M 2026-06
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Cara Therapeutics USD -2.39M 3.16M 2025-03
Corcept Therapeutics USD -49M 53.2M 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Eisai JPY 34.15B 34.48B 2026-06
Eli Lilly USD 10.29B 1.86B 2026-03
Incyte USD 778.57M 410.6M 2026-06
J&J USD 8.27B 1.08B 2026-03
Moderna USD -1.26B 468M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Pfizer USD 6.01B 18M 2026-06
Prothena USD 25.98M 65.51M 2026-03
PTC Therapeutics USD 61.98M 132.97M 2026-03
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Vanda Pharmaceuticals USD -8.31M 2.37M 2024-12
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06